SCHEMBL6408001

SCHEMBL6408001

NC(=O)c1csc2c1CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.54
ALDH1A1 P00352 6/20 0.51
HTT P42858 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMN1; SMN2 Q16637 6/20 0.49
MAPT P10636 6/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KDM4E B2RXH2 1/20 0.49
RECQL P46063 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 2/20 0.48
HSD17B10 Q99714 2/20 0.48
TSHR P16473 1/20 0.48
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
STAT3 P40763 1/20 0.47
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.46
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3121683 0.96 HPGD (0.58) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL2182641 0.94 HPGD (0.61) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL22775116 0.82 HPGD (0.56) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL1121822 0.78 HPGD (0.60) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL10367333 0.77 SMN1; SMN2 (0.59) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL29503118 0.77 HPGD (0.63) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL21797959 0.77 HPGD (0.55) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL18430429 0.77 HPGD (0.58) HPGDALDH1A1HTTL3MBTL1SMN1; SMN2
SCHEMBL4781326 0.76 MAPK8 (0.35) HPGDALDH1A1HTTL3MBTL1MAPT
SCHEMBL351180 0.75 PNMT (0.43) HPGDALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090871-A1 ELECTROPHILIC PURINE COMPOUNDS FOR MODIFICATION OF PROTEINS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2025-05-01 WO disclosed
US-11807618-B2 Thiophene derivatives as antiviral agents ENYO PHARMA (FR) 2023-11-07 US disclosed
US-11760733-B2 Small molecule regulators of mitochondrial fusion and methods of use thereof WASHINGTON UNIVERSITY (US) 2023-09-19 US disclosed
US-20220213053-A1 THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS ENYO PHARMA (FR) 2022-07-07 US disclosed
US-11279683-B2 Thiophene derivatives as antiviral agents ENYO PHARMA (FR) 2022-03-22 US disclosed
CN-110114349-B Thiophene derivatives as antiviral agents 埃尼奥制药公司 2022-03-15 CN disclosed
US-20050288347-A1 Certain triazole-based compounds, compositions, and uses thereof AGRIUS GROUP, LLC. 2005-12-29 US disclosed
WO-2005033102-A2 THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMPHORA DISCOVERY CORPORATION (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213053-A1 THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS MAVS, EIF2AK2, IRF3 HPGD 4196/4885ALDH1A1 3437/4885HTT 2322/4885
US-11760733-B2 Small molecule regulators of mitochondrial fusion and methods of use thereof MFN2, FIS1, RHOT2 HPGD 1662/4885ALDH1A1 4127/4885HTT 403/4885
US-20050288347-A1 Certain triazole-based compounds, compositions, and uses thereof ABCG2, ATP5ME, DNTT HPGD 835/4885ALDH1A1 720/4885HTT 2113/4885
US-11279683-B2 Thiophene derivatives as antiviral agents MAVS, EIF2AK2, IRF3 HPGD 4008/4885ALDH1A1 1759/4885HTT 3585/4885
US-11807618-B2 Thiophene derivatives as antiviral agents MAVS, EIF2AK2, IRF3 HPGD 4196/4885ALDH1A1 3437/4885HTT 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.